BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 7688657)

  • 1. Significance of abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue.
    Deitch AD; Miller GJ; deVere White RW
    Cancer; 1993 Sep; 72(5):1692-700. PubMed ID: 7688657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA flow cytometric study of the hyperplastic and neoplastic canine prostate.
    Madewell BR; Deitch AD; Higgins RJ; Marks SL; deVere White RW
    Prostate; 1991; 18(2):173-9. PubMed ID: 1706513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors.
    Zincke H; Bergstralh EJ; Larson-Keller JJ; Farrow GM; Myers RP; Lieber MM; Barrett DM; Rife CC; Gonchoroff NJ
    Cancer; 1992 Jul; 70(1 Suppl):311-23. PubMed ID: 1600493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications.
    Tinari N; Natoli C; Angelucci D; Tenaglia R; Fiorentino B; Di Stefano P; Amatetti C; Zezza A; Nicolai M; Iacobelli S
    Cancer; 1993 Feb; 71(4):1289-96. PubMed ID: 8435806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA heterogeneity in prostatic adenocarcinoma. A DNA flow cytometric mapping study with whole organ sections of prostate.
    O'Malley FP; Grignon DJ; Keeney M; Kerkvliet N; McLean C
    Cancer; 1993 May; 71(9):2797-802. PubMed ID: 8467459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA ploidy and proliferation heterogeneity in human prostate cancers.
    Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
    Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of nuclear DNA ploidy patterns in patients with prostate cancer after radical prostatectomy.
    Wirth MP; Müller HA; Manseck A; Müller J; Frohmüller HG
    Eur Urol; 1991; 20(3):248-52. PubMed ID: 1823048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In treating localized prostate cancer the efficacy of cryoablation is independent of DNA ploidy type.
    Bahn DK; Silverman P; Lee F; Badalament R; Bahn ED; Rewcastle JC
    Technol Cancer Res Treat; 2004 Jun; 3(3):253-7. PubMed ID: 15161318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
    Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
    Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA ploidy in prostate cancer: potential measurement as a surrogate endpoint biomarker.
    Lieber MM
    J Cell Biochem Suppl; 1994; 19():246-8. PubMed ID: 7529855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer.
    Häggarth L; Auer G; Busch C; Norberg M; Häggman M; Egevad L
    Scand J Urol Nephrol; 2005; 39(5):387-92. PubMed ID: 16257840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.
    Badalament RA; O'Toole RV; Young DC; Drago JR
    Cancer; 1991 Jun; 67(12):3014-23. PubMed ID: 1710533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma--necessitating multiple site analysis.
    Warzynski MJ; Soechtig CE; Maatman TJ; Goldsmith LC; Grobbel MA; Carothers GG; Shockley KF
    Prostate; 1995 Dec; 27(6):329-35. PubMed ID: 7501545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Near tetraploid prostate carcinoma. Methodologic and prognostic aspects.
    Forsslund G; Nilsson B; Zetterberg A
    Cancer; 1996 Oct; 78(8):1748-55. PubMed ID: 8859188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of DNA ploidy in carcinoma of prostate.
    Dejter SW; Cunningham RE; Noguchi PD; Jones RV; Moul JW; McLeod DG; Lynch JH
    Urology; 1989 May; 33(5):361-6. PubMed ID: 2711553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation.
    Pollack A; Troncoso P; Zagars GK; von Eschenbach AC; Mak AC; Wu CS; Terry NH
    Prostate; 1997 Apr; 31(1):21-8. PubMed ID: 9108882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.
    Montgomery BT; Nativ O; Blute ML; Farrow GM; Myers RP; Zincke H; Therneau TM; Lieber MM
    Arch Surg; 1990 Mar; 125(3):327-31. PubMed ID: 2306181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA flow cytometry in carcinoma of the prostate for diagnosis, prognosis and study of tumor biology.
    Tribukait B
    Acta Oncol; 1991; 30(2):187-92. PubMed ID: 2029403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis.
    Nativ O; Winkler HZ; Raz Y; Therneau TM; Farrow GM; Myers RP; Zincke H; Lieber MM
    Mayo Clin Proc; 1989 Aug; 64(8):911-9. PubMed ID: 2796401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.